Publisher： Bentham Science Publishers
E-ISSN： 2212-3903|7|2|117-122
ISSN： 1574-8855
Source： Current Drug Therapy, Vol.7, Iss.2, 2012-06, pp. : 117-122
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The use and indications of anti-vascular endothelial growth factors (VEGF) are rapidly expanding, evolving and undergoing refinement in retinal diseases. This manuscript attempts to perform a critical appraisal of the diaspora of limited information available on the non- traditional applications (outside of AMD, DR and vascular occlusive diseases) and synthesize a review. As with any newer drug, only longitudinal studies will determine the true inherent value no matter how broad the current popular appeal appears to be due to very positive press. Although these drugs appear to be very effective in conventional applications, it is wise to deliberate prior to non-conventional use.
Related content
Anti-VEGF Treatment of Glaucoma
Current Drug Therapy, Vol. 7, Iss. 2, 2012-06 ,pp. :
Access to resources
Recommend
Anti-VEGF Treatment of Diabetic Retinopathy
Current Drug Therapy, Vol. 7, Iss. 2, 2012-06 ,pp. :
Anti-VEGF Treatment of Anterior Segment Disorders of the Eye
Current Drug Therapy, Vol. 7, Iss. 2, 2012-06 ,pp. :
Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy, Vol. 1, Iss. 3, 2006-09 ,pp. :
Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy, Vol. 7, Iss. 2, 2012-06 ,pp. :